company background image
0X40 logo

AgeX Therapeutics DB:0X40 Stock Report

Last Price

€17.44

Market Cap

€29.0m

7D

0%

1Y

-19.3%

Updated

26 Mar, 2024

Data

Company Financials

0X40 Stock Overview

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. More details

0X40 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

AgeX Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AgeX Therapeutics
Historical stock prices
Current Share PriceUS$17.44
52 Week HighUS$23.56
52 Week LowUS$10.06
Beta1.19
11 Month Change55.97%
3 Month Change49.40%
1 Year Change-19.35%
33 Year Change-62.14%
5 Year Changen/a
Change since IPO-88.23%

Recent News & Updates

Recent updates

Shareholder Returns

0X40DE BiotechsDE Market
7D0%-0.7%-0.02%
1Y-19.3%-17.2%8.2%

Return vs Industry: 0X40 underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: 0X40 underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is 0X40's price volatile compared to industry and market?
0X40 volatility
0X40 Average Weekly Movement19.3%
Biotechs Industry Average Movement6.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.3%

Stable Share Price: 0X40's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0X40's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20176Joanne Hackettwww.agexinc.com

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company’s lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology.

AgeX Therapeutics, Inc. Fundamentals Summary

How do AgeX Therapeutics's earnings and revenue compare to its market cap?
0X40 fundamental statistics
Market cap€29.02m
Earnings (TTM)-€13.63m
Revenue (TTM)€130.77k

221.9x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0X40 income statement (TTM)
RevenueUS$142.00k
Cost of RevenueUS$40.00k
Gross ProfitUS$102.00k
Other ExpensesUS$14.91m
Earnings-US$14.80m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.92
Gross Margin71.83%
Net Profit Margin-10,424.65%
Debt/Equity Ratio81.5%

How did 0X40 perform over the long term?

See historical performance and comparison